NCT04827862View on ClinicalTrials.gov

RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

July 1, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Non Hodgkin Lymphoma
Interventions
DRUG

Pembrolizumab

pembrolizumab plus low-dose (4 Gy x 5) involved-site radiotherapy

Trial Locations (1)

19104

Abamson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER